BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 38592451)

  • 1. Cyclooxygenase-2-prostaglandin E2-eicosanoid receptor inflammatory axis: a key player in Kaposi's sarcoma-associated herpes virus associated malignancies.
    Paul AG; Chandran B; Sharma-Walia N
    Transl Res; 2013 Aug; 162(2):77-92. PubMed ID: 23567332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines.
    Carbone A; Cesarman E; Gloghini A; Drexler HG
    AIDS; 2010 Feb; 24(4):479-90. PubMed ID: 20051807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden.
    White MC; Wong JP; Damania B
    Cancer Res Commun; 2024 Apr; 4(4):1024-1040. PubMed ID: 38592451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KSHV/HHV-8 latency with COX-2 selective inhibitor nimesulide: a potential chemotherapeutic modality for primary effusion lymphoma.
    Paul AG; Sharma-Walia N; Chandran B
    PLoS One; 2011; 6(9):e24379. PubMed ID: 21980345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pyrrolidinium fullerene induces apoptosis by activation of procaspase-9 via suppression of Akt in primary effusion lymphoma.
    Watanabe T; Nakamura S; Ono T; Ui S; Yagi S; Kagawa H; Watanabe H; Ohe T; Mashino T; Fujimuro M
    Biochem Biophys Res Commun; 2014 Aug; 451(1):93-100. PubMed ID: 25063029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor.
    Lan K; Murakami M; Bajaj B; Kaul R; He Z; Gan R; Feldman M; Robertson ES
    Cancer Biol Ther; 2009 Nov; 8(22):2136-43. PubMed ID: 19783901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMO Modification of Histone Demethylase KDM4A in Kaposi's Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.
    Yeh WW; Chen YQ; Yang WS; Hong YC; Kao S; Liu TT; Chen TW; Chang L; Chang PC
    J Virol; 2022 Aug; 96(16):e0075522. PubMed ID: 35914074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary Effusion Lymphoma: A Clinicopathologic Perspective.
    Gathers DA; Galloway E; Kelemen K; Rosenthal A; Gibson SE; Munoz J
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
    Zhang X; Huang X; Xu J; Li E; Lao M; Tang T; Zhang G; Guo C; Zhang X; Chen W; Yadav DK; Bai X; Liang T
    Nat Commun; 2021 Jul; 12(1):4536. PubMed ID: 34315872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Inhibition of Akt and mTOR Is Effective Against Non-Hodgkin Lymphomas.
    Rivera-Soto R; Yu Y; Dittmer DP; Damania B
    Front Oncol; 2021; 11():670275. PubMed ID: 34221985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance.
    Xiao H; Zheng Y; Ma L; Tian L; Sun Q
    Front Pharmacol; 2021; 12():648407. PubMed ID: 33953682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ABC transporter expression and mutational status on survival rates of cancer patients.
    Kadioglu O; Saeed MEM; Munder M; Spuller A; Greten HJ; Efferth T
    Biomed Pharmacother; 2020 Nov; 131():110718. PubMed ID: 32932043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription.
    Oh SS; Lee KW; Madhi H; Jeong JW; Park S; Kim M; Lee Y; Han HT; Hwangbo C; Yoo J; Kim KD
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32131547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy.
    Chuang SH; Lee YE; Huang LYL; Chen CK; Lai CL; Lin YH; Yang JY; Yang SC; Chang LH; Chen CH; Liu CW; Lin HS; Lee YR; Huang KP; Fu KC; Jen HM; Lai JY; Jian PS; Wang YC; Hsueh WY; Tsai PY; Hong WH; Chang CC; Wu DZ; Wu J; Chen MH; Yu KM; Chern CY; Chang JM; Lau JYN; Huang JJ
    Eur J Med Chem; 2020 Apr; 191():112118. PubMed ID: 32113126
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.